A thirty-year innovation gap ends as next-generation targeted therapies for Primary Biliary Cholangitis Singapore arrive, bringing vital relief to women suffering from misdiagnosed, life-altering symptoms.
For many women living with Primary Biliary Cholangitis (PBC), the hardest part of the condition is not the diagnosis itself. The true challenge lies in the years it can take to get there. Relentless itching and crushing fatigue are easily written off as menopause, stress, or simply getting older.
Primary Biliary Cholangitis (PBC) remains a complex and widely misunderstood condition within the healthcare landscape of Singapore. It is a chronic autoimmune disease that gradually destroys the bile ducts in the liver. This condition affects women in roughly nine out of ten cases.
Because the early progression of the disease does not usually present with other symptoms, it is regularly mistaken for ordinary fatigue. Consequently, a significant gap remains between the onset of the condition and a definitive diagnosis.
Fortunately, as medical awareness grows, the outlook for patients in Singapore is entering a more hopeful chapter. The clinical community is preparing for a new class of breakthrough targeted therapies, representing the first major treatment innovation for PBC in three decades.
A Disease That Hides in Plain Sight
In a healthy liver, bile ducts act as a plumbing system to drain toxins away. For patients with PBC, the immune system mistakenly attacks these ducts. This attack leads to a toxic build-up of bile acids that causes chronic inflammation.
If left unmanaged, this slow progression can result in permanent liver scarring, also known as cirrhosis. Eventually, the damage can progress to complete liver failure.
Catching the disease early is the central challenge for clinicians. This difficulty exists largely because the most common symptoms leave no visible physical markers. Therefore, they are easily dismissed by patients and doctors alike.
Itching (pruritus): This is an intense, internal sensation that cannot be relieved by scratching. It often leads to severe sleep deprivation. The symptom affects up to three-quarters of people living with PBC at some point during their disease.
Fatigue: This manifests as an all-encompassing exhaustion. It makes everyday tasks feel insurmountable, affecting up to 80 per cent of people living with PBC.
These symptoms rarely show up on a routine blood test. This exact factor is what makes PBC so easy to miss during initial consultations.
When Stable Lab Results Do Not Tell the Whole Story
A patient may present with stable liver enzyme levels. Yet, she may remain unable to sleep, concentrate at work, or engage fully with her family.
This situation creates a central disconnect in care. For a long time, the medical community assumed that satisfactory biochemistry meant a patient was thriving.
“If a patient continues to suffer from life-altering symptoms like relentless itching or extreme fatigue, their treatment cannot be considered fully effective, regardless of what the biochemistry suggests.” — Professor Gideon Hirschfield of the University of Toronto.
This insight serves as a reminder for many women. The numbers on a lab report and the reality of daily life can tell two completely different stories.
Closing a 30-Year Treatment Gap
For the past three decades, the standard treatment framework for PBC has been limited. It relied primarily on ursodeoxycholic acid (UDCA). While UDCA slows the disease down for many patients, it leaves roughly 40 per cent of people with an incomplete response. This group remains at ongoing risk of advanced liver damage.
“Although there are some treatments for itch in PBC patients, approximately 40 per cent of patients do not respond to treatment. Severe, intractable itch is an indication for liver transplantation,” says Dr Thinesh Lee Krishnamoorthy, Senior Consultant at the Department of Gastroenterology and Hepatology at Singapore General Hospital (SGH) states in CNA.
A new generation of targeted therapies is now arriving in Singapore. These drugs are designed specifically to address the biological pathways that traditional treatments miss. These therapies focus on the specific mechanisms of bile acid production. They offer a customised option for patients who previously had no further avenues of treatment.
The next-generation therapies arriving in Singapore include elafibranor, registered locally in September 2025, and seladelpar. These options have shown response rates of roughly 50 per cent to 60 per cent among non-responsive patients.
Rather than simply managing secondary effects, these therapies regulate bile acid production at the cellular level. “Both drugs have also demonstrated improvements in itch symptom scores, which is a major step forward in treating the disease,” notes Dr Thinesh.
For patients who have lived for years with few options, this precise mechanism of action offers profound relief. It brings renewed hope.
A Region Stepping Up for Rare Disease Care
Across the ASEAN region, an estimated 9 per cent of the population is living with a rare condition (Shafie et al., 2016). However, awareness and regulatory infrastructure remain in early development in several neighbouring countries.
Singapore’s leadership in this space lies in its ability to provide clear clinical pathways. It brings visibility to conditions that have historically been the hardest to diagnose.
Singapore’s robust rare disease framework is supported by initiatives such as the Rare Disease Fund (RDF). This framework includes a 3-to-1 government matching grant (Ministry of Health Singapore, 2019).
Such funding ensures that the healthcare infrastructure is well placed to adopt new clinical pathways. By encouraging proactive screening for at-risk demographics, Singapore is moving towards a more predictable future for those living with PBC.
References:
- Galoosian A, et al. 2020. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol. 8(1), pp. 49-60.
- Ali AH, Byrne TJ, Lindor KD. 2015. Orphan drugs in development for primary biliary cirrhosis: challenges and progress. Orphan Drugs: Research and Reviews. 5(1), pp..83-97 numbers.
- Selmi C, et al. 2007. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology. 46(6), pp.1836-1843.
- Gungabissoon U, et al. 2022. Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis. BMJ Open Gastroenterol. 9(1), p.e000857.
- Chalifoux SL, et al. 2017. Extrahepatic Manifestations of Primary Biliary Cholangitis. Gut Liver. 11(6):771
- Hirschfield, G. M. (2024). Re-imagining primary biliary cholangitis care: Patient-centric, utilising biochemistry, controlling symptoms. EMJ Hepatology, 12(1), 2–10
- Ratziu V, et al. 2016. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterol. 150:1147-1159 e5
- Ministry of Health Singapore. (2023, November 22). Rare Disease Fund. https://www.moh.gov.sg/newsroom/rare-disease-fund
- Primary Biliary Cholangitis. British Liver Trust. https://britishlivertrust.org.uk/information-and-support/liver-conditions/primary-biliary-cholangitis/.
